Because NAB2 acts a suppressing regulator for EGR1 transcription factor, a defective NAB2 fused with the TAD of STAT6 leads to constitutive activation of EGR‐mediated transcription targets, notably NAB2, NAB1, IGF2, EGF2, PDGFD, FGFR1, and NTRK1. NAB2‐STAT6 fusion is considered a tumor‐initiating event across benign and malignant SFTs. The gene discussed is STAT6; the disease is neoplasm.